Cost Per Response Analysis of Nivolumab Versus Everolimus in the Treatment of Patients Previously Treated with Advanced Renal Cell Carcinoma – Brazil Private Health Care System Perspective

OBJECTIVES: Nivolumab demonstrated a significant survival benefit when compared with everolimus (median OS 25.0 vs 19.6 months; hazard ratio: 0.73, P=0.002) in a randomized Phase III trial conducted in patients with advanced renal cell carcinoma (aRCC) who had received previous anti-angiogenic treat...

Full description

Saved in:
Bibliographic Details
Published in:Value in health 2017-10, Vol.20 (9), p.A875
Main Authors: Brust, L, Bernardino, G, Aratangy, G, Tanaka, S, Paladini, L, Borges, L, Clark, OA
Format: Article
Language:English
Subjects:
Angiogenesis
Cancer therapies
Critical incidents
Drug prices
Health care expenditures
Immunotherapy
Inhibitor drugs
Kidney cancer
Kidney diseases
Medical treatment
Monoclonal antibodies
Patients
Private medical care
Renal cell carcinoma
Targeted cancer therapy
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:OBJECTIVES: Nivolumab demonstrated a significant survival benefit when compared with everolimus (median OS 25.0 vs 19.6 months; hazard ratio: 0.73, P=0.002) in a randomized Phase III trial conducted in patients with advanced renal cell carcinoma (aRCC) who had received previous anti-angiogenic treatment. Similarly, a substantially higher objective response rates favouring patients receiving nivolumab (25.1% vs 5.4%; odds ratio: 5.98, p
ISSN:1098-3015
1524-4733
DOI:10.1016/j.jval.2017.08.2579